Department of Radiology, Kobe Comprehensive Medical College, 7-1-21 Tomugaoka, Suma-ku, Kobe-shi, Hyogo 654-0142, Japan.
Faculty of Advanced Techno‑Surgery, Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8‑1 Kawada‑cho, Shinjuku‑ku, Tokyo 162‑8666, Japan.
J Neurooncol. 2023 Feb;161(3):555-562. doi: 10.1007/s11060-023-04244-3. Epub 2023 Feb 7.
To retrospectively evaluate preoperative clinical factors for their ability to preoperatively differentiate malignancy grades in patients with incipient supratentorial grade II/III diffuse gliomas.
This retrospective study included 206 adult patients with incipient supratentorial grade II/III diffuse gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. The cohort included 136 men and 70 women, with a median age of 41 years. Preoperative factors included age, sex, presence of calcifications on computed tomography scans, and preoperative tumor volume measured using preoperative magnetic resonance imaging.
In patients with oligodendrogliomas (IDH-mutant and 1p/19q-codeleted), calcifications were significantly more frequent (p = 0.0034) and tumor volume was significantly larger (p < 0.001) in patients with grade III tumors than in those with grade II tumors. Moreover, in patients with IDH-mutant astrocytomas, preoperative tumor volume was significantly larger (p = 0.0042) in patients with grade III tumors than in those with grade II tumors. In contrast, none of the evaluated preoperative clinical factors were significantly different between the patients with grade II and III IDH-wildtype astrocytomas.
In adult patients with suspicison incipient supratentorial grade II/III diffuse gliomas, presence of calcifications and larger preoperative tumor volume might be used as preoperative indices to differentiate between malignancy grades II and III in oligodendrogliomas (IDH-mutant and 1p/19q-codeleted) and larger preoperative tumor volume might have similar utility in IDH-mutant astrocytomas.
回顾性评估术前临床因素在预测初发幕上 II/III 级弥漫性神经胶质瘤患者恶性程度分级中的能力。
本回顾性研究纳入了 206 名根据 2016 年世界卫生组织中枢神经系统肿瘤分类诊断为初发幕上 II/III 级弥漫性神经胶质瘤的成年患者。该队列包括 136 名男性和 70 名女性,中位年龄为 41 岁。术前因素包括年龄、性别、计算机断层扫描(CT)上有无钙化以及术前磁共振成像(MRI)测量的术前肿瘤体积。
在少突胶质细胞瘤(IDH 突变且 1p/19q 缺失)患者中,III 级肿瘤患者的钙化明显更常见(p=0.0034),肿瘤体积明显更大(p<0.001)。此外,在 IDH 突变型星形细胞瘤患者中,III 级肿瘤患者的术前肿瘤体积明显更大(p=0.0042)。相比之下,在 IDH 野生型星形细胞瘤患者中,II 级和 III 级肿瘤患者的所有评估术前临床因素均无显著差异。
在怀疑初发幕上 II/III 级弥漫性神经胶质瘤的成年患者中,存在钙化和较大的术前肿瘤体积可能被用作术前指数来区分 IDH 突变型少突胶质细胞瘤(IDH 突变且 1p/19q 缺失)的 II 级和 III 级肿瘤,以及 IDH 突变型星形细胞瘤中较大的术前肿瘤体积可能具有相似的作用。